Is there anything that cannabidiol (CBD) can’t do? The hemp extract has proven quite effective at managing an astonishing number of diseases, with the list ranging from insomnia and anxiety to chronic pain and high blood pressure.
In June 2018, the FDA has approved a CBD-based drug to treat seizures in two rare and hard to manage childhood epilepsies, Lennox-Gastaut syndrome, and Dravet syndrome.
There has also been interest in CBD as an alternative treatment for psoriasis. This is a condition that speeds up the life cycle of skin cells, leading to a rapid build-up of extra skin. The build-up forms dry, itchy red skin lesions, referred to as plaque psoriasis, usually at the back of the elbows, over the kneecaps and on the lower back.
The condition is often accompanied by arthritis, and there’s currently no cure. Usually, the goal of treatment is to slow down the build-up of skin.
According to a study published in the Journal of Dermatological Science in February 2007, cannabidiol may slow down the rapid growth of certain skin cells.
A 2018 sweeping review of all the data gathered from research on CBD’s dermatological benefits stated that “cannabinoids have shown some initial promise as a therapy for a variety of skin diseases, including psoriasis.” However, it highlighted the need for more high quality randomized clinical trials.
“We know that cannabinoids like CBD can reduce inflammation and pain, but most of what we’re seeing right now is that most of the evidence is circumstantial but promising,” says David Casarett, Chief of Palliative Care at Duke University in Durham.
Another study led by researchers in Italy found that “topical treatment with CBD-enriched ointment significantly improved the skin parameters, the symptoms and also the PASI index score. No irritant or allergic reaction was documented during the treatment period.”
The study concluded that “the topical administration of CBD ointment, without any THC, is a safe and effective non-invasive alternative to improve the quality of life in patients with some skin disorders, especially on the inflammatory background.”
“However, while these studies are generally encouraging,” says Dr. Jordan Tishler, a Boston-based Physician and cannabis expert, “they’re nowhere near conclusive.”
On the other hand, Nerve Dramas, a physician at Grassroots Medicine and Wellness, a cannabis medical practice in Miami, uses CBD as part of the psoriasis treatment plans he recommends to his patients.
“For dermatological issues such as psoriasis, dermatitis, and eczema, I’ve found CBD to be very effective at decreasing the flare-ups, irritation and discomfort my patients’ experience.”
It is generally agreed that such reports of the benefits of cannabidiol bring a smile to companies like Grapefruit Boulevard Investments Inc. (OTCQB: IGNG) and Dama Financial since they derive strength by seeing how different groups of people are benefitting from their products.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.